Skip to main content
PMC home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1996 Jan;49(1):65–67. doi: 10.1136/jcp.49.1.65

Inverse correlation between Helicobacter pylori infection and inflammatory bowel disease.

L Halme 1, H Rautelin 1, M Leidenius 1, T U Kosunen 1
PMCID: PMC1023160  PMID: 8666689

Abstract

AIMS: To determine the seroprevalence of Helicobacter pylori in patients with Crohn's disease or ulcerative colitis and in controls without inflammatory bowel disease (IBD). METHODS: One hundred consecutive patients with Crohn's disease, 100 consecutive patients with ulcerative colitis, and 100 age and sex matched controls were studied. Serum H pylori IgG and IgA antibody titres were measured by enzyme immunoassay. RESULTS: The seroprevalence of H pylori was 15% in patients with IBD (13% in patients with Crohn's disease and 18% in patients with ulcerative colitis), whereas the corresponding figure for the controls was 43%. When compared with controls, the seroprevalence of H pylori in patients with IBD was considerably lower in all age groups tested. There was no important difference in treatment with sulphasalazine or in any other medical therapy administered to H pylori positive and negative patients. At the time of blood sampling there was no difference in the level of education or in the employment status between the patients and the controls. CONCLUSIONS: Patients with IBD were less likely to be infected with H pylori than their age and sex matched controls. Neither medical treatment nor socioeconomic factors could explain the difference.

Full text

PDF
67

Images in this article

66Image
on p.66

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Banatvala N., Mayo K., Megraud F., Jennings R., Deeks J. J., Feldman R. A. The cohort effect and Helicobacter pylori. J Infect Dis. 1993 Jul;168(1):219–221. doi: 10.1093/infdis/168.1.219. [DOI] [PubMed] [Google Scholar]
  2. Ekbom A., Wakefield A. J., Zack M., Adami H. O. Perinatal measles infection and subsequent Crohn's disease. Lancet. 1994 Aug 20;344(8921):508–510. doi: 10.1016/s0140-6736(94)91898-8. [DOI] [PubMed] [Google Scholar]
  3. Gent A. E., Hellier M. D., Grace R. H., Swarbrick E. T., Coggon D. Inflammatory bowel disease and domestic hygiene in infancy. Lancet. 1994 Mar 26;343(8900):766–767. doi: 10.1016/s0140-6736(94)91841-4. [DOI] [PubMed] [Google Scholar]
  4. Giaffer M. H., Holdsworth C. D., Duerden B. I. Virulence properties of Escherichia coli strains isolated from patients with inflammatory bowel disease. Gut. 1992 May;33(5):646–650. doi: 10.1136/gut.33.5.646. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Hopkins R. J., Vial P. A., Ferreccio C., Ovalle J., Prado P., Sotomayor V., Russell R. G., Wasserman S. S., Morris J. G., Jr Seroprevalence of Helicobacter pylori in Chile: vegetables may serve as one route of transmission. J Infect Dis. 1993 Jul;168(1):222–226. doi: 10.1093/infdis/168.1.222. [DOI] [PubMed] [Google Scholar]
  6. Ibbotson J. P., Lowes J. R., Chahal H., Gaston J. S., Life P., Kumararatne D. S., Sharif H., Alexander-Williams J., Allan R. N. Mucosal cell-mediated immunity to mycobacterial, enterobacterial and other microbial antigens in inflammatory bowel disease. Clin Exp Immunol. 1992 Feb;87(2):224–230. doi: 10.1111/j.1365-2249.1992.tb02979.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Kosunen T. U., Hök J., Rautelin H. I., Myllylä G. Age-dependent increase of Campylobacter pylori antibodies in blood donors. Scand J Gastroenterol. 1989 Jan;24(1):110–114. doi: 10.3109/00365528909092247. [DOI] [PubMed] [Google Scholar]
  8. Kosunen T. U., Seppälä K., Sarna S., Sipponen P. Diagnostic value of decreasing IgG, IgA, and IgM antibody titres after eradication of Helicobacter pylori. Lancet. 1992 Apr 11;339(8798):893–895. doi: 10.1016/0140-6736(92)90929-w. [DOI] [PubMed] [Google Scholar]
  9. Mendall M. A., Goggin P. M., Molineaux N., Levy J., Toosy T., Strachan D., Northfield T. C. Childhood living conditions and Helicobacter pylori seropositivity in adult life. Lancet. 1992 Apr 11;339(8798):896–897. doi: 10.1016/0140-6736(92)90931-r. [DOI] [PubMed] [Google Scholar]
  10. Mitchell H. M., Li Y. Y., Hu P. J., Liu Q., Chen M., Du G. G., Wang Z. J., Lee A., Hazell S. L. Epidemiology of Helicobacter pylori in southern China: identification of early childhood as the critical period for acquisition. J Infect Dis. 1992 Jul;166(1):149–153. doi: 10.1093/infdis/166.1.149. [DOI] [PubMed] [Google Scholar]
  11. Sanderson J. D., Moss M. T., Tizard M. L., Hermon-Taylor J. Mycobacterium paratuberculosis DNA in Crohn's disease tissue. Gut. 1992 Jul;33(7):890–896. doi: 10.1136/gut.33.7.890. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Sørensen V. Z., Olsen B. G., Binder V. Life prospects and quality of life in patients with Crohn's disease. Gut. 1987 Apr;28(4):382–385. doi: 10.1136/gut.28.4.382. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Taha A. S., Sturrock R. D., Russell R. I. Helicobacter pylori and peptic ulcers in rheumatoid arthritis patients receiving gold, sulfasalazine, and nonsteroidal anti-inflammatory drugs. Am J Gastroenterol. 1992 Dec;87(12):1732–1735. [PubMed] [Google Scholar]
  14. el-Omar E., Penman I., Cruikshank G., Dover S., Banerjee S., Williams C., McColl K. E. Low prevalence of Helicobacter pylori in inflammatory bowel disease: association with sulphasalazine. Gut. 1994 Oct;35(10):1385–1388. doi: 10.1136/gut.35.10.1385. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES